Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(8):501; doi:10.1093/jnci/djj178
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Surrogate Endpoint for Prostate Cancer Outcome

Clinical trials of new drugs could be speeded up if researchers could measure surrogate endpoints (e.g., biomarkers) that completely capture the true outcomes of interest (e.g., survival). Several statistical criteria have been developed that can be used to validate a candidate surrogate endpoint. In this issue, Petrylak et al. (p. 516) report a retrospective analysis of data on survival and serum prostate-specific antigen (PSA) levels from a clinical trial in men with metastatic androgen-independent prostate cancer, which showed that several specific changes in PSA level met these criteria. The optimal surrogate endpoint was a decline in serum PSA level of at . . . [Full Text of this Article]

Functional Limitations in Elderly Cancer Survivors

Assessing Prostate Cancer Risk

Breast Implants and Cancer

Reproductive Factors, BRCA1/2, and Breast Cancer

Antitumor Activity of Novel PI3K Inhibitor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?